RankingsPricing
  1. US-listed companies
  2. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.HEPA

Market cap
$2.94M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Jun 30,
2014		Jun 30,
2015		Jun 30,
2016		Jun 30,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Research and development314,2468151483122033
General and administrative16677581010
Impairment of goodwill--------2
Total operating expenses--2121158203045
Loss from operations-1,672,109-13,959,979-20,805,485-21,023,872-14,594,159-7,770,085-20,146,075-30,403,309-45,488,726
Interest expense-----554,99831,2298,85910,164
Change in fair value of contingent consideration-----558,715-146,050-2,310,000414,992
Loss before income taxes----16,799,053-9,985,295-7,946,020-20,323,354-33-45
Income tax benefit (expense)----1,908,003-536,000-1,227,32230,584--3
Net loss--14,347,877-16,998,638-14,891,050-9,449,295-6,718,698-20,353,938-32,722,168-42,200,049
Deemed dividend (see Note 4)--------3
Net loss available to common stockholders, basic-5,280,842-22,192,520--14,891,050-17,901,146-12,161,645-20,359,225-32,722,168-45,337,549
Net loss attributable to common stockholders, diluted--------32,722,168-45,337,549
Earnings Per Share, Basic----0.26-1.39---0.47-0.59
Earnings Per Share, Diluted----0.3-1.39---0.47-0.59